AHA shares proposals to lower Medicare drug prices with Congress
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Headline
The House June 4 passed the AHA-supported SUPPORT Act (H.R. 2483) by a 366-57 vote. The legislation reauthorizes key prevention, treatment and recovery…
Headline
Sens. Chuck Schumer, D-N.Y., Susan Collins, R-Maine, and Andy Kim, D-N.J., June 5 reintroduced the SEPSIS Act, legislation which would task the Centers for…
Perspective
As Reconciliation Bill Shifts to the Senate, We Must Speak Up to Protect Medicaid and Access to Care
After approval in the House last week by a one vote margin, the One Big Beautiful Bill Act — a sweeping package that would enact many of President Trump’s…
Headline
AHA May 23 submitted recommendations to the Department of Justice and Federal Trade Commission in response to the agencies’ requests for information on…
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
The House Budget Committee May 18 advanced the fiscal year 2025 budget reconciliation bill by a 17-16 vote along party lines, as four Republicans who…